Journal of International Oncology››2020,Vol. 47››Issue (6): 340-345.doi:10.3760/cma.j.cn371439-20200103-00032
• Orginal Articles •Previous ArticlesNext Articles
Wang Lili1, Zhao Song1, Ouyang Mingyue1, Xie Xiaodong2, Xing Sining1, Liu Shuo1, Yu Huiying1()
Received:
2020-01-03Revised:
2020-04-07Online:
2020-06-08Published:
2020-07-22Contact:
Yu Huiying E-mail:hyingy@sina.comSupported by:
Wang Lili, Zhao Song, Ouyang Mingyue, Xie Xiaodong, Xing Sining, Liu Shuo, Yu Huiying. Role of docetaxel induced polyploid tumor cells in tumor recurrence[J]. Journal of International Oncology, 2020, 47(6): 340-345.
[1] | Zhang S, Mercado-Uribe I, Xing Z, et al. Generation of cancer stem-like cells through the formation of polyploid giant cancer cells[J]. Oncogene, 2014,33(1):116-128. DOI: 10.1038/onc.2013.96. doi:10.1038/onc.2013.96 |
[2] | Coward J, Harding A. Size does matter: why polyploid tumor cells are critical drug targets in the war on cancer[J]. Front Oncol, 2014,4:123. DOI: 10.3389/fonc.2014.00123. doi:10.3389/fonc.2014.00123pmid:24904834 |
[3] | Amend SR, Torga G, Lin KC, et al. Polyploid giant cancer cells: unrecognized actuators of tumorigenesis, metastasis, and resistance[J]. Prostate, 2019,79(13):1489-1497. DOI: 10.1002/pros.23877. doi:10.1002/pros.23877pmid:31376205 |
[4] | 杜均祥, 彭东旭, 潘莹, 等. Tau低表达对肺腺癌患者多西他赛化疗敏感性及疾病进展时间关系的研究[J]. 临床肺科杂志, 2019,24(6):1111-1115. DOI: 10.3969/j.issn.1009-6663.2019.06.037. |
[5] | 鲁凯, 刘燕文, 李惠, 等. BRCA1在乳腺癌中的表达及与多西他赛疗效的关系[J]. 中华内分泌外科杂志, 2016,10(5):382-385. DOI: 10.3760/cma.j.issn.1674-6090.2016.05.008. |
[6] | Ishida S, Masuguchi K, Kawashiri T, et al. Effects of diluent volume and administration time on the incidence of anaphylaxis following docetaxel therapy in breast cancer[J]. Biol Pharm Bull, 2020,43(4):663-668. DOI: 10.1248/bpb.b19-00876. doi:10.1248/bpb.b19-00876pmid:32238707 |
[7] | 于卉影, 孙英慧, 蔺迪, 等. 肿瘤患者自体CIK细胞输注增强再次制备时CD3+CD56+细胞的体外扩增能力 [J]. 细胞与分子免疫学杂志, 2014,30(7):748-753, 758. |
[8] | 李淑青, 陈亚萍. 卵巢癌对顺铂和紫杉醇耐药的分子机制[J]. 国际妇产科学杂志, 2016,43(2):145-150. |
[9] | 张赛, 邱明宁, 汤焕城, 等. 去势抵抗性前列腺癌发生多西他赛耐药的相关机制及其治疗进展[J]. 肿瘤, 2016,36(10):1165-1170. DOI: 10.3781/j.issn.1000-7431.2016.55.436. |
[10] | Ogden A, Rida PC, Knudsen BS, et al. Docetaxel-induced polyploidization may underlie chemoresistance and disease relapse[J]. Cancer Lett, 2015,367(2):89-92. DOI: 10.1016/j.canlet.2015.06.025. doi:10.1016/j.canlet.2015.06.025pmid:26185000 |
[11] | Tsubaki M, Takeda T, Ogawa N, et al. Overexpression of survivin via activation of ERK1/2, Akt, and NF-κB plays a central role in vincristine resistance in multiple myeloma cells[J]. Leuk Res, 2015,39(4):445-452. DOI: 10.1016/j.leukres.2015.01.016. doi:10.1016/j.leukres.2015.01.016pmid:25726084 |
[12] | Mittal K, Donthamsetty S, Kaur R, et al. Multinucleated polyploidy drives resistance to docetaxel chemotherapy in prostate cancer[J]. Br J Cancer, 2017,116(9):1186-1194. DOI: 10.1038/bjc.2017.78. doi:10.1038/bjc.2017.78pmid:28334734 |
[13] | Yeung KT, Yang J. Epithelial-mesenchymal transition in tumor metastasis[J]. Mol Oncol, 2017,11(1):28-39. DOI: 10.1002/1878-0261.12017. doi:10.1002/1878-0261.12017pmid:28085222 |
[14] | Mittal V. Epithelial mesenchymal transition in tumor metastasis[J]. Annu Rev Pathol, 2018,13:395-412. DOI: 10.1146/annurev-pathol-020117-043854. doi:10.1146/annurev-pathol-020117-043854pmid:29414248 |
[15] | Papadaki MA, Stoupis G, Theodoropoulos PA, et al. Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metasta-tic breast cancer[J]. Mol Cancer Ther, 2019,18(2):437-447. DOI: 10.1158/1535-7163.MCT-18-0584. doi:10.1158/1535-7163.MCT-18-0584pmid:30401696 |
[16] | van Staalduinen J, Baker D, Ten Dijke P, et al. Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?[J]. Oncogene, 2018,37(48):6195-6211. DOI: 10.1038/s41388-018-0378-x. doi:10.1038/s41388-018-0378-xpmid:30002444 |
[17] | Schmeel LC, Schmeel FC, Coch C, et al. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international re-gistry on CIK cells (IRCC)[J]. J Cancer Res Clin Oncol, 2015,141(5):839-849. DOI: 10.1007/s00432-014-1864-3. doi:10.1007/s00432-014-1864-3pmid:25381063 |
[18] | Introna M. CIK as therapeutic agents against tumors[J]. J Autoi-mmun, 2017,85:32-44. DOI: 10.1016/j.jaut.2017.06.008. |
[19] | 梁雪峰, 郑振东, 朴瑛, 等. 自体CIK细胞治疗联合 DP 方案一线化疗治疗晚期肺腺癌临床研究[J]. 肿瘤预防与治疗, 2013,26(2):68-71. DOI: 10.3969/j.issn.1674-0904.2013.02.003. |
[20] | 李宁, 田永巍, 高岭, 等. 自体CIK细胞联合放化疗治疗中晚期子宫颈癌的疗效[J]. 中国肿瘤生物治疗杂志, 2016,23(6):830-834. DOI: 10.3872/j.issn.1007-385X.2016.06.016. |
[1] | Xiong Chan, Yan Ying, Xie Xiaodong, Meng Fanjie, Yu Huiying.Study on the biological characteristics of polyploid cervical cancer HeLa cells induced by radiation[J]. Journal of International Oncology, 2022, 49(5): 263-269. |
[2] | Geng Hui, Hu Fengchao, Lu Hongchao, Guo Jungang, Qi Zengping.Effects of TPF regimen and IMRT on immune function and survival prognosis of patients with advanced esophageal cancer[J]. Journal of International Oncology, 2022, 49(2): 84-88. |
[3] | Jing Wenjun, Zhao Wenwen, Feng Qingqing, Zhao Wenfei, Zhao Lili, Zhang Xue, Wei Hongmei.Molecular basis and clinical prospect of the miR-34 family for the treatment of gastric cancer[J]. Journal of International Oncology, 2022, 49(11): 681-686. |
[4] | Yan Xingyu, Lian Zhenying, Diao Yutao, Liu Hongyan.BMXΔN mediates gefitinib resistance of lung cancer cells through ERK/MAPK signaling pathway[J]. Journal of International Oncology, 2021, 48(6): 328-334. |
[5] | Hou Jianghou, Yao Yingjie, Zhan Xiaoyan, Yang Yimei.Regulation of EMT in lung cancer cells by interaction of Hsp90 and SIRT1[J]. Journal of International Oncology, 2021, 48(4): 200-205. |
[6] | Zhao Lili, Zhao Wenwen, Feng Qingqing, Zhao Wenfei, Zhang Xue, Jing Wenjun, Wei Hongmei.Effects of silencing PD-L1 expression on biological behaviors of gastric cancer cells[J]. Journal of International Oncology, 2021, 48(12): 705-710. |
[7] | Wang Ningju, Chen Dongmei, Zhang Heng, Hu Ping, Wang Yan.Effects of targeted silencing of PRL-3 gene on proliferation, migration, invasion and epithelial-mesenchymal transition of lung cancer cells[J]. Journal of International Oncology, 2021, 48(1): 18-23. |
[8] | Chen Long, Lin Ling, Wang Cuiying, Wang Lin, He Donglei, Feng Jun.Clinical research of intercalated combination of osimertinib and docetaxel in T790M mutationpositive lung adenocarcinoma patients with bone metastasis in the southern Hainan Province[J]. Journal of International Oncology, 2019, 46(7): 399-403. |
[9] | Tang Shimin, Liu Li, Dong Huaqiong.Clinical observation of apatinib combined with docetaxel in treatment of advanced serum alpha-fetoprotein-positive gastric cancer[J]. Journal of International Oncology, 2019, 46(4): 221-225. |
[10] | Li Wenqing, Hou Jinsong.Epigenetic regulation of epithelial-mesenchymal transition[J]. Journal of International Oncology, 2017, 44(12): 918-921. |
[11] | Yang Shirong, Zhao Chengmao, Wang Rong, Mu Yuanzhong, Zhao Gang.Clinical evaluation of oxaliplatin combined with S-1 or docetaxel for advanced gastric cancer[J]. Journal of International Oncology, 2015, 42(6): 426-429. |
[12] | Shan Zezhi, Yan Xuebing, Tian Yuan, Jin Zhiming.Mechanism research of Tbx3 gene in tumor progression[J]. Journal of International Oncology, 2015, 42(1): 37-39. |
[13] | Yan Xuebing, Yan Leilei, Liu Sihong, Shan Zezhi, Jin Zhiming.Expression of Y-box-binding protein-1 and epithelialmesenchymal transition markers in colorectal cancer[J]. Journal of International Oncology, 2014, 41(8): 624-628. |
[14] | QIANG Su-Feng, HUANG Yong.Epithelial-mesenchymal transition and cancer stem cells[J]. Journal of International Oncology, 2013, 40(3): 177-181. |
[15] | LIU Li-Min, LI Ji-Kun.Epithelial-mesenchymal transition and gastric cancer[J]. Journal of International Oncology, 2013, 40(12): 924-926. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||